Fabio P.
- Country
- Italy
- Department
- Oncology
Research Overview
- Palazestrant and Ribociclib versus Letrozole and Ribociclib for First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Phase III Trial of BNT327 plus Combination Chemotherapy versus Placebo plus Chemotherapy in Patients with Previously Untreated Metastatic or Locally Recurrent Triple-Negative Breast Cancer
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
Data & Insights
Has run more than one trial at 385 of 690 partner sites.
Specializations
HER2-Positive Breast Cancer
The investigator specializes in treating HER2-positive breast cancer across various stages, with particular focus on evaluating novel therapeutic approaches using targeted therapies.
- Early-stage HER2+ treatment
- Metastatic HER2+ interventions
- High-risk residual disease management
Research encompasses innovative antibody-drug conjugates and combination therapies for HER2+ breast cancer patients.
Hormone Receptor-Positive Disease
Significant expertise in hormone receptor-positive breast cancer treatment, particularly focusing on endocrine therapy resistance and novel therapeutic combinations.
- Advanced HR+/HER2- breast cancer
- CDK4/6 inhibitor combinations
- Early-stage hormone-positive disease
Investigates innovative approaches for hormone-resistant disease and treatment optimization strategies.
Triple-Negative Breast Cancer
Conducts research in triple-negative breast cancer treatment modalities, with emphasis on immunotherapy combinations and targeted approaches.
- Metastatic TNBC management
- Immunotherapy combinations
- Novel therapeutic strategies
Focuses on developing effective treatments for this aggressive breast cancer subtype.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.